scholarly journals Purine deoxynucleosides and adenosine dialdehyde decrease 5-amino-4-imidazolecarboxamide (Z-base)-dependent purine nucleotide synthesis in cultured T and B lymphoblasts

1987 ◽  
Vol 242 (2) ◽  
pp. 425-431 ◽  
Author(s):  
G R Boss

Deoxyadenosine (dAdo) and deoxyguanosine (dGuo) decrease methionine synthesis from homocysteine in cultured lymphoblasts; because of the possible trapping of 5-methyltetrahydrofolate this could lead to decreased purine nucleotide synthesis. Since purine deoxynucleosides could also inhibit purine synthesis de novo at an early step not involving folate metabolism, we measured in azaserine-treated cells 5-amino-4-imidazolecarboxamide (Z-base)-dependent purine nucleotide synthesis using [14C]formate. In the T lymphoblasts, Z-base-dependent purine nucleotide synthesis was decreased 26% by 0.3 microM-dAdo, 21% by 1 microM-dGuo and 28% by 1 microM-adenosine dialdehyde, a potent S-adenosylhomocysteine hydrolase inhibitor; homocysteine fully reversed the inhibitions. The B lymphoblasts were considerably less sensitive to the deoxynucleoside-induced decrease in Z-base-dependent purine nucleotide synthesis, with 100 microM-dAdo required for significant inhibition and no inhibition by dGuo at this concentration; homocysteine partly reversed the inhibition by dAdo. The observed decrease in Z-base-dependent purine nucleotide synthesis could not be attributed either to dUMP depletion changing the folate pools or to decreased ATP availability because dUrd was without effect and during the experimental period the intracellular ATP concentration did not change significantly. Cells with 5,10-methylenetetrahydrofolate reductase deficiency were relatively resistant to inhibition of Z-base-dependent purine nucleotide synthesis by dAdo and adenosine dialdehyde. Our results suggest that deoxynucleosides decrease purine nucleotide synthesis by trapping 5-methyltetrahydrofolate.

1981 ◽  
Vol 9 (2) ◽  
pp. 300P-300P
Author(s):  
L. THUILLIER ◽  
F. GARREAU ◽  
P. CARTIER

2008 ◽  
Vol 3 (8) ◽  
pp. 499-511 ◽  
Author(s):  
Heather L. Schultheisz ◽  
Blair R. Szymczyna ◽  
Lincoln G. Scott ◽  
James R. Williamson

Author(s):  
Neal S. LeLeiko ◽  
Andrew D. Bronstein ◽  
B. Surendra Baliga ◽  
Hamish N. Munro

2014 ◽  
Vol 2014 ◽  
pp. 1-12 ◽  
Author(s):  
Nazanin Majd ◽  
Kazutaka Sumita ◽  
Hirofumi Yoshino ◽  
Dillon Chen ◽  
Jumpei Terakawa ◽  
...  

Tumor cells adapt to their high metabolic state by increasing energy production. To this end, current efforts in molecular cancer therapeutics have been focused on signaling pathways that modulate cellular metabolism. However, targeting such signaling pathways is challenging due to heterogeneity of tumors and recurrent oncogenic mutations. A critical need remains to develop antitumor drugs that target tumor specific pathways. Here, we discuss an energy metabolic pathway that is preferentially activated in several cancers as a potential target for molecular cancer therapy. In vitro studies have revealed that many cancer cells synthesize guanosine triphosphate (GTP), via the de novo purine nucleotide synthesis pathway by upregulating the rate limiting enzyme of this pathway, inosine monophosphate dehydrogenase (IMPDH). Non-proliferating cells use an alternative purine nucleotide synthesis pathway, the salvage pathway, to synthesize GTP. These observations pose IMPDH as a potential target to suppress tumor cell growth. The IMPDH inhibitor, mycophenolate mofetil (MMF), is an FDA-approved immunosuppressive drug. Accumulating evidence shows that, in addition to its immunosuppressive effects, MMF also has antitumor effects via IMPDH inhibition in vitro and in vivo. Here, we review the literature on IMPDH as related to tumorigenesis and the use of MMF as a potential antitumor drug.


1994 ◽  
Vol 22 (2) ◽  
pp. 241S-241S ◽  
Author(s):  
DISPENSA EGIDIO ◽  
FILIPPO CARLUCCI ◽  
ELENA CONSOLMAGNO ◽  
PIERO GALIENI ◽  
ROBERTO LEONCINI ◽  
...  

1989 ◽  
Vol 38 (22) ◽  
pp. 4045-4051 ◽  
Author(s):  
E. Colleen Moore ◽  
Robert B. Hurlbert ◽  
Gerry R. Boss ◽  
Steve P. Massia

Sign in / Sign up

Export Citation Format

Share Document